Volitinib in Treating Patients With Recurrent or Refractory Primary CNS Tumors

Phase 1

Volitinib in Treating Patients With Recurrent or Refractory Primary CNS TumorsVolitinib in Treating Patients With Recurrent or Refractory Primary CNS Tumors

Sponsor:

National Cancer Institute (NCI)

Code:

NCT03598244

Conditions

Recurrent Diffuse Intrinsic Pontine Glioma

Recurrent Malignant Glioma

Recurrent Medulloblastoma

Recurrent Primary Central Nervous System Neoplasm

Refractory Diffuse Intrinsic Pontine Glioma

Eligibility Criteria

Sex: All

Age: 6 - 21

Healthy Volunteers: Not accepted

Interventions

Biospecimen Collection

Magnetic Resonance Imaging

Savolitinib

X-Ray Imaging

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-03-29. This information was provided to ClinicalTrials.gov by National Cancer Institute (NCI) on 2025-03-26.